How do you plan to integrate nerandomilast into the treatment algorithm for patients with ILD?  

That’s a great question and one we’re all still actively defining in real time as this new agent enters practice.First, I always start with the basics—diagnosis and disease behavior. Before starting any antifibrotic, I make sure the ILD diagnosis is solid through multidisciplinary review and t...